Affinity Investment Advisors LLC Sells 2,852 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Affinity Investment Advisors LLC trimmed its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 41.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,102 shares of the medical equipment provider’s stock after selling 2,852 shares during the quarter. Affinity Investment Advisors LLC’s holdings in Lantheus were worth $254,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of LNTH. FMR LLC raised its holdings in shares of Lantheus by 198.2% in the 3rd quarter. FMR LLC now owns 2,146,085 shares of the medical equipment provider’s stock valued at $149,110,000 after purchasing an additional 1,426,465 shares during the period. Norges Bank acquired a new position in Lantheus in the 4th quarter valued at about $29,956,000. Reinhart Partners LLC. grew its stake in Lantheus by 50.4% in the 4th quarter. Reinhart Partners LLC. now owns 1,356,273 shares of the medical equipment provider’s stock valued at $84,089,000 after buying an additional 454,753 shares during the last quarter. Rhenman & Partners Asset Management AB grew its stake in Lantheus by 439.0% in the 3rd quarter. Rhenman & Partners Asset Management AB now owns 538,986 shares of the medical equipment provider’s stock valued at $37,449,000 after buying an additional 438,986 shares during the last quarter. Finally, Fiera Capital Corp acquired a new position in Lantheus in the 3rd quarter valued at about $30,077,000. 99.06% of the stock is owned by institutional investors.

Insider Transactions at Lantheus

In other news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $76.89, for a total transaction of $26,219.49. Following the completion of the sale, the chief accounting officer now owns 62,898 shares of the company’s stock, valued at approximately $4,836,227.22. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the stock in a transaction on Wednesday, March 6th. The stock was acquired at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the transaction, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at approximately $4,836,227.22. The disclosure for this sale can be found here. In the last 90 days, insiders sold 94,545 shares of company stock valued at $6,177,295. Company insiders own 2.10% of the company’s stock.

Lantheus Price Performance

Shares of Lantheus stock traded up $0.31 on Wednesday, reaching $81.01. 239,567 shares of the stock were exchanged, compared to its average volume of 1,044,684. The firm’s 50 day moving average is $66.00 and its 200-day moving average is $63.73. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $100.48. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.55 and a current ratio of 4.84. The firm has a market cap of $5.61 billion, a PE ratio of 12.32 and a beta of 0.52.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The company had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 5.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LNTH has been the topic of a number of research reports. Truist Financial upped their price target on shares of Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. B. Riley upped their price target on shares of Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. JMP Securities restated a “market outperform” rating and set a $100.00 target price on shares of Lantheus in a research report on Friday, February 23rd. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Finally, Mizuho increased their target price on shares of Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.17.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.